ZA902519B - Pharmaceutical formulations - Google Patents

Pharmaceutical formulations

Info

Publication number
ZA902519B
ZA902519B ZA902519A ZA902519A ZA902519B ZA 902519 B ZA902519 B ZA 902519B ZA 902519 A ZA902519 A ZA 902519A ZA 902519 A ZA902519 A ZA 902519A ZA 902519 B ZA902519 B ZA 902519B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical formulations
formulations
pharmaceutical
Prior art date
Application number
ZA902519A
Other languages
English (en)
Inventor
Michael Jon Pikal
Jon Pikal Michael
Michael Larry Roy
Larry Roy Michael
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA902519B publication Critical patent/ZA902519B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44Antibodies bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6805Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a vinca alkaloid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA902519A 1989-04-04 1990-04-02 Pharmaceutical formulations ZA902519B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33315489A 1989-04-04 1989-04-04

Publications (1)

Publication Number Publication Date
ZA902519B true ZA902519B (en) 1991-12-24

Family

ID=23301547

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA902519A ZA902519B (en) 1989-04-04 1990-04-02 Pharmaceutical formulations

Country Status (8)

Country Link
EP (1) EP0392717A1 (fr)
JP (1) JPH02290822A (fr)
KR (1) KR900015760A (fr)
AU (1) AU5252090A (fr)
CA (1) CA2013600A1 (fr)
HU (1) HUT54308A (fr)
IL (1) IL93986A0 (fr)
ZA (1) ZA902519B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9418092D0 (en) * 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
FR2853551B1 (fr) 2003-04-09 2006-08-04 Lab Francais Du Fractionnement Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee
EP1532983A1 (fr) 2003-11-18 2005-05-25 ZLB Bioplasma AG Preparation d'immunoglobulines à stabilité élevée
TWI398272B (zh) 2005-03-08 2013-06-11 Intervet Int Bv 化學定義的安定劑
US7705132B2 (en) 2006-10-20 2010-04-27 Amgen Inc. Stable polypeptide formulations
FR2910812B1 (fr) 2006-12-29 2009-03-20 Pierre Fabre Medicament Sa Compositions pharmaceutiques injectables lyophilisees de derives hemi-synthetiques d'alcaloide de vinca stables a temperature ambiante
ES2716088T3 (es) 2010-02-04 2019-06-10 Csl Behring Ag Preparado de inmunoglobulina
EP2361636A1 (fr) 2010-02-26 2011-08-31 CSL Behring AG Préparation d'immunoglobuline et système de stockage pour préparation d'immunoglobuline

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1254057A (en) * 1969-04-24 1971-11-17 Louisette Olivier Improvements in or relating to therapeutical composition containing vincamine
IL82579A0 (en) * 1986-05-27 1987-11-30 Lilly Co Eli Immunoglobulin conjugates
ZA89524B (en) * 1988-01-27 1990-09-26 Lilly Co Eli Antibody conjugates
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation

Also Published As

Publication number Publication date
AU5252090A (en) 1990-10-11
EP0392717A1 (fr) 1990-10-17
HU902047D0 (en) 1990-08-28
HUT54308A (en) 1991-02-28
CA2013600A1 (fr) 1990-10-04
IL93986A0 (en) 1991-01-31
KR900015760A (ko) 1990-11-10
JPH02290822A (ja) 1990-11-30

Similar Documents

Publication Publication Date Title
EP0366277A3 (en) Pharmaceutical formulations
ZA902519B (en) Pharmaceutical formulations
EP0409499A3 (en) Pharmaceutical compositions
AP9000236A0 (en) Pharmaceutical formulations
GB8917959D0 (en) Pharmaceutical formulation
CS343490A3 (en) Pharmaceutical
GB8919456D0 (en) Pharmaceutical formulations
GB8918809D0 (en) Pharmaceutical formulations
GB8919595D0 (en) Pharmaceutical formulations
GB8919597D0 (en) Pharmaceutical formulations
GB8926946D0 (en) Pharmaceutical formulations
IE894215L (en) Pharmaceutical formulations
GB8820272D0 (en) Pharmaceutical formulations
GB8813402D0 (en) Pharmaceutical formulations
GB8816609D0 (en) Pharmaceutical formulations
GB8828994D0 (en) Pharmaceutical formulations
GB8820175D0 (en) Pharmaceutical formulations
IE882439L (en) Pharmaceutical formulations
GB8825297D0 (en) Pharmaceutical formulations
GB8820343D0 (en) Pharmaceutical formulations
GB8820273D0 (en) Pharmaceutical formulations
GB8810733D0 (en) Pharmaceutical formulations
GB8820271D0 (en) Pharmaceutical formulations
GB8804790D0 (en) Pharmaceutical formulations
GB8919592D0 (en) Pharmaceutical formulation